Alwaleed Philanthropies, a charitable and philanthropic organisation, is investing USD5m in its collaboration with Gavi, the Vaccine Alliance, it was reported on Sunday.
The commitment will offer extra funding between 2020 and 2024 to support organisations known by Gavi as 'pacesetters' that are developing new innovations to improve vaccine access and delivery, particularly in urban areas. The investment will be made through Gavi's INFUSE initiative (Innovation for Uptake, Scale and Equity in Immunisation), which identifies these 'pacesetters', offers funding and support for them, and connects them to authorities in countries that required vaccination support.
The grant is part of a range of efforts by Alwaleed Philanthropies to improve routine immunisation and contributes to Gavi's mission to ensure that every child is immunised with basic life-saving vaccines, no matter where they live, and builds on the original USD1m investment made in 2015 to support vaccines in Timor Leste, Kiribati, Armenia, Azerbaijan, Moldova, Guyana for the 2016-2020 programme.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine